Gennady Nikitin

Switzerland
Bulle, Fribourg, Switzerland

Company profile

Gennady Nikitin company profile

Gennady Nikitin developed a novel fluorescent mitochondrial pH probe to identify the metabolic profiles of various cancers. These phenotypes can then be used to screen metabolism-targeting anti-cancer drugs, to discover which will be most effective against each type of cancer. Finding metabolic profiles that are unique to cancerous cells, and absent in healthy cells, will be of special interest.

Business identity

Operating status
Active
Company type
For Profit

Headquarters

Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
1
Total equity funding
$9,893
Last funding
Pre Seed / $9,893 / 2019-05-17
Last equity funding
Pre Seed / $9,893

Founders and investors

No public relation records are available.